Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
OBJECTIVE
To identify the effect of price control policies on drug expenditure in South Korea.


METHODS
We retrospectively examined the effects of price-reduction policies on drug expenditures, in particular regarding anti-hyperlipidemic drugs. The National Health Insurance claims data for a 60-month period between 2006 and 2010 were analysed. A segmented regression analysis was conducted with three intervention variables: July 2008, April 2009, and January 2010.


RESULTS
Despite three rounds of price cuts, monthly drug expenditures increased by KRW 599.67 million (USD 523,726) after the third intervention (p=0.0781). The trend in volume increased consistently, but not significantly. The unit prices showed a steady downward trend over time, but rebounded after the third price cut. The number of patients with hyperlipidemia more than doubled to 3729 (p=0.0801) per month after the entry of generics for atorvastatin in July 2008.


CONCLUSIONS
Extensive price controls did not effectively suppress the growth of pharmaceutical expenditures. The increased number of patients, attributable to the newly launched generic drug atorvastatin, and the increased use of expensive drugs were major factors affecting the increase in drug spending. Policies that regulate both drug prices and utilisation, and that reduce financial burdens via enhanced use of generics need to be introduced.
Institute of Health and Environment, Seoul National University, Seoul, South Korea.
Hye-Young
HY
Kwon
Ji-Min
JM
Hong
Brian
B
Godman
Bong-Min
BM
Yang
D003363:Cost Control; D016527:Drug Costs / Q000706:statistics & numerical data*; D004335:Drug and Narcotic Control; D017850:Economics, Pharmaceutical; D005102:Health Expenditures / Q000706:statistics & numerical data*; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics*; D007349:Insurance, Health, Reimbursement / Q000191:economics; D056910:Republic of Korea; D012189:Retrospective Studies
D000960:Hypolipidemic Agents
Antihyperlipidemics; Drug utilisation; Pharmaceutical expenditures; Price control; Price reduction